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Abstract: 
Objective. To describe the implementation, work flow, and differences in outcomes 
between a pharmacist-managed clinic for the outpatient treatment of venous 
thromboembolism (VTE) using rivaroxaban versus care by a primary care provider. 
Interventions. Patients in the studied health system that are diagnosed with low-risk VTE in 
the emergency department are often discharged without hospital admission. These patients 
are treated with rivaroxban and follow up either in a pharmacist-managed VTE clinic or with 
their primary care provider. Pharmacists in the VTE clinic work independently under a 
collaborative practice agreement. An evaluation of thirty-four patients, seventeen in each 
treatment arm, was conducted to compare the differences in treatment-related outcomes 
of rivaroxaban when managed by a pharmacist versus a primary care provider.  
Results. The primary endpoint was a six month composite of anticoagulation treatment-
related complications that included a diagnosis of major bleeding, recurrent 
thromboembolism, or fatality due to either major bleeding or recurrent thromboembolism. 
Secondary endpoints included number of hospitalizations, adverse events, and medication 
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adherence. There was no difference in the primary endpoint between groups with one 
occurrence of the composite endpoint in each treatment arm (p=1.000), both of which were 
recurrent thromboembolic events. Medication adherence assessment was formally 
performed in 8 patients in the pharmacist group versus 0 patients in the control group. No 
differences were seen amongst other secondary endpoints. 
Conclusions. The pharmacist-managed clinic is a novel expansion of clinical pharmacy 
services that treats patients with low-risk VTEs with rivaroxaban in the outpatient setting. 
The evaluation of outcomes provides support that pharmacist-managed care utilizing 
standardized protocols under a collaborative practice agreement may be as safe as care by a 
primary care provider.  
 
Introduction: 
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), affects approximately 1 in 1000 people in the United States annually.1-2 
Treatment consists of anticoagulation therapy, and evidence supports treating patients with 
low-risk VTEs as outpatients.3-5 Novel oral anticoagulants such as rivaroxaban, an oral factor 
Xa inhibitor, are FDA approved for the treatment of VTE and serve as an alternative 
therapeutic option to a parenteral anticoagulant and warfarin, as it does not require 
bridging therapy. As demonstrated in the EINSTEIN clinical trial, benefits to using 
rivaroxaban for outpatient VTE therapy instead of warfarin include less frequent monitoring, 
less major bleeding, fewer drug interactions, and simpler dosing regimens.6 
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Development of Outpatient Venous Thromboembolism Clinic 
The outpatient VTE clinic, also known as the clot clinic, was originally developed by 
emergency department (ED) physicians in March of 2013 as an un-funded, ED fellowship 
research project. Protocols were established for the outpatient treatment of VTE that 
included initial clinic visits between two and five weeks to establish care and again three to 
six months after diagnosis to determine duration of therapy.  In anticipation of the fellows’ 
graduation, the physicians engaged the pharmacy department for assistance with 
transitioning the clinic's management to clinical pharmacists. During a six month overlap 
period, internal medicine and critical care-trained clinical pharmacists shadowed, trained, 
and created a hospital leadership approved collaborative practice agreement outlining 
specific protocols and medication management procedures. Upon completion of the 
fellowship, pharmacy assumed the responsibilities of the clot clinic as an opportunity to 
expand outpatient clinical pharmacy services. After clinic implementation, pharmacists 
performed a study evaluating the difference in outcomes between the outpatient treatment 
of VTE with rivaroxaban in the pharmacist-managed clinic versus management by a primary 
care provider (PCP). 
 
Methods: 
Study Setting 
The clot clinic is located within an academic, safety-net, level 1 trauma center in a 
metropolitan city. The clinic takes place once monthly for four hours and provides services 
for up to twelve outpatients with low-risk VTE treated with rivaroxaban.  The two clinical 
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pharmacists that manage the clot clinic and facilitate patient visits dedicate this time in 
addition to their normal, full-time jobs providing clinical pharmacy support to internal 
medicine and critical care teams. This equates to a combined total of 0.05 FTE monthly.     
 
Study Design 
This prospective, observational cohort study evaluated the difference in outcomes between 
the outpatient treatment of VTE with rivaroxaban in a pharmacist-managed clinic versus 
management by a PCP. Outcomes were evaluated for patients seen between April 2015 and 
September 2015. The protocol was approved by the Indiana University Health Institutional 
Review Board prior to initiation of the study.  
 
Patients in the pharmacist-managed group were diagnosed by a physician with a low-risk 
VTE based on the absence of any Hestia criteria  in the ED.7 For example, patients eligible for 
referral were required to have normal renal function (creatinine clearance > 30 ml/min), a 
systolic blood pressure above 100 mm Hg and a pulse oximetry reading above 94%, did not 
warrant admission for other medical or social conditions, and were not exhibiting 
coagulopathy based on international normalized ratio (INR) for the prothrombin time (PT)   
and had a a normal platelet count. After diagnosis and ensuring eligibility criteria were met, 
patients were discharged from the ED with a prescription for rivaroxaban and a clot clinic 
appointment scheduled within one month from presentation. As a safety-net health-system, 
all referred patients are evaluated in clot clinic, regardless of payor source or insurance 
status.    
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Comparator group patients were selected using the hospital system’s outpatient pharmacy 
dispense records. From the list of rivaroxaban prescriptions filled, patients were evaluated 
using the hospital’s electronic medical record system and were included for potential 
matching if rivaroxaban was being used to treat a VTE. Once identified for potential 
matching, the control group patient was matched with a pharmacist-managed patient if 
they met all the following criteria: month and year of rivaroxaban initiation, age (same 
decade of life), and sex.  
 
Study Protocol 
The clot clinic pharmacist is able to order laboratory tests and manage medications in 
accordance with the collaborative practice agreement (CPA) between the clot clinic 
physicians and pharmacist. Laboratory tests including anti-Xa levels, basic metabolic panels, 
complete blood counts, D-dimers, and PT/INRs can be ordered based on the patient’s 
history, presentation, or potential drug-drug interactions. Aspirin is considered an 
independent privilege, meaning it can be started, renewed, adjusted, or discontinued by the 
pharmacist. The pharmacist can renew, adjust, or discontinue rivaroxaban, warfarin, and 
enoxaparin prescriptions if originally prescribed by a physician. Any ED physician can write 
the original prescriptions for patients treated in the pharmacist-managed clinic. 
Prothrombin complex concentrate (PCC) and vitamin K can only be prescribed after provider 
consultation (but has not been used in any case).  
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Patient information collected at the pharmacist-managed clinic visit is summarized in Table 
1. Prior to seeing the patient, the pharmacist reviews the patient’s electronic medical record 
to analyze VTE diagnosis, laboratory data, and medication list. During each visit, the 
pharmacist identifies VTE symptoms, performs a focused physical exam (e.g. skin 
assessment, calf measurements, and pain evaluation), and evaluates for post-thrombotic 
syndrome (a syndrome resulting from thrombotic venous scarring and valve destruction 
leading to long term pain and changes in blood flow).8,9 Assessment of adherence is 
performed using the 4-item Modified Morisky Adherence Scale, a validated questionnaire 
tool for measuring medication adherence.10 Patients are counseled on laboratory results, 
medication use, adherence, side effects, drug interactions, lifestyle modifications, smoking 
cessation, and other issues as they arise. The pharmacist determines the duration of 
therapy, in alignment with the CHEST guidelines, primarily based on patient biological sex, 
location and nature of clot (i.e. DVT or PE, provoked or unprovoked) and if the patient has 
prior history of VTE. D-dimer concentrations can be used to help determine appropriate 
therapy duration in uncertain cases.11,12 A unique contribution to clinic services provided by 
the pharmacists includes assistance with navigating insurance-related issues including prior 
authorizations, patient assistance programs, and other sources of sustainable funding to 
facilitate medication access and ensure completion of therapy.   
 
Outcomes 
The primary outcome was the composite occurrence of anticoagulation treatment-related 
complications defined as an episode of major bleeding, recurrent thromboembolic event, or 
fatal event due to either bleeding or thromboembolism within six months of the original VTE 
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diagnosis. The study defined major bleeding using the International Society for Thrombosis 
and Hemostasis definition of greater than or equal to a 2 g/dL reduction in hemoglobin or 
greater than or equal to 2 units of blood transfusion, bleeding in a critical area, or bleeding 
contributing to death.13 Secondary endpoints included individual components of the 
primary outcome, number of hospitalizations after VTE diagnosis, adverse events, and 
Morisky medication adherence score.  
 
Data Analysis 
Statistical tests were performed using Minitab® 16 statistical software (Minitab Inc., State 
College, PA). Normally distributed data were reported with mean (standard deviation), 
whereas non-normally distributed data were reported with median (interquartile range). 
Normality was tested using the Anderson-Darling Normality Test. The student’s t-test was 
used to detect differences between normally distributed continuous data. For continuous 
data that was not normally distributed, a Mann-Whitney U test was used to examine 
potential differences. The Fisher’s exact or Chi-square tests were used to detect differences 
in nominal data. The significance level (alpha) was pre-determined to be less than 0.05. A 
sample size calculation was not conducted as this was a convenience sample limited to the 
number of patients seen and treated in the described clinic with a corresponding number of 
control patients.  
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Results: 
Seventeen patients were seen in the pharmacist-managed clinic during the six-month study 
period. The mean patient age was 50 (+12) years, and six patients were male (35%). 
Seventeen patients served as matching cohorts in the control group with a mean patient age 
of 54 (+12) years, six of whom were male (35%). Patients were well-matched in terms of 
age, gender, weight, smoking status, and occurrence of either DVT and/or PE. Complete 
demographic information is summarized in Table 2.  
 
Primary Outcome 
There was one occurrence (6%) of the composite primary endpoint in each study arm, each 
of which were due to recurrent thromboembolic events (p=1.000). These events were 
within the first six months of original VTE diagnosis and both were recurrent DVTs. 
 
Secondary Outcomes 
All secondary outcomes are summarized in Table 3. There was one instance (6%) of VTE-
related hospitalization in each study arm (p=1.000). All other hospitalizations were not 
related to the patients' VTE diagnosis or treatment. Adverse events described by patients 
included pain, headache, and minor bleeding including menorrhagia. Overall, there were 
seven (41%) reported adverse events in the pharmacist care group and four (24%) in the 
control group (p=0.465).  
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Pharmacists began using the Modified Morisky Adherence Scale to formally evaluate 
medication adherence three months after starting in the clot clinic since it had not been 
studied in this patient population to our knowledge. While this could influence the 
secondary endpoint of medication adherence, it was determined to be a necessary part of 
our study protocol because a lack of adherence could negatively affect patient care, directly 
impacting the primary outcome. All patients assessed (n=8) had a score of 0 or 1, signifying 
high adherence. Although a few PCP notes commented on a patient’s medication adherence 
informally, no patients in the control group had a documented assessment of medication 
adherence using a formal tool. The lack of formal assessment in the control group could 
represent a confounder to the results.  
 
Discussion: 
Pharmacists have demonstrated the importance of their role in the outpatient health care 
setting based on studies showing improved patient outcomes, medication adherence, and 
compliance to evidence-based guidelines. Examples include increased percentage of 
patients on optimally dosed heart failure medications, increased medication adherence 
leading to decreased heart failure-related ED visits, increased percentage of patients with 
hypertension achieving goal blood pressures, and decreases in hemoglobin A1c in patients 
with diabetes.14-17 Previously published studies on pharmacist-managed warfarin clinics 
describe the pharmacist’s ability to achieve goal INRs more frequently than PCPs, improve 
patient satisfaction scores, and decrease costs by optimizing the number of INRs checked.18-
20 The pharmacist-managed clot clinic is a unique expansion of outpatient clinical pharmacy 
services. In the clot clinic, not only are pharmacists managing and monitoring 
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anticoagulants, they are also independently managing VTE treatment duration, assessing 
adherence, and ensuring sustainability of drug therapy. 
 
This study compares patient outcomes in the pharmacist-managed clinic versus those 
managed by a PCP. Because the pharmacist-managed clinic is the only formalized outpatient 
service treating patients with low-risk VTE, there were challenges in selecting a control 
group. A few control group patients were hospitalized as a result of their original VTE 
diagnosis, potentially selecting for a higher-risk control group. It was not possible to 
retrospectively evaluate the severity of VTE using the Hestia criteria in the control group due 
to documentation limitations in the electronic medical record. Restrictive, pre-determined 
inclusion criteria were used for control group patients to ensure they were matched as 
closely as possible with intervention group patients. The goal of a matched control group 
was to minimize confounders allowing for a more accurate comparison of pharmacist-
managed versus PCP-managed care.  
 
Although a power calculation was not performed due to the convenience sample of our 
study, the primary outcome indicated pharmacist-managed care was potentially as safe as 
care by a PCP and helped justify long-term pharmacist management in the clinic. The similar 
secondary outcome results further support the safety of a pharmacist-managed clinic. A 
post-hoc power calculation demonstrated that in order to achieve 80% power to detect at 
least a 10% difference in the primary outcome between study groups, 153 patients would 
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need to be enrolled in each arm of the study. Based on current enrollment rates, this would 
take at least 6 years with our single center.    
 
There were a higher number of documented adverse events noted in the pharmacist-
managed group, which could be due to recall bias. However, given the small number of 
events overall, this may have been due to differences in the questions asked to the patient 
and documentation practices. By using a standardized question list and note template, 
pharmacists ensured they would not omit asking about or reporting adverse events. 
Menorrhagia was the most common adverse event reported by female patients in the clot 
clinic. To address this concern, the pharmacist-managed protocol specifies holding no more 
than one dose of rivaroxaban if the patient has heavy uterine bleeding (i.e. menstrual 
bleeding considered heavy by the patient and lasting five or more days, or two consecutive 
days requiring ten or more pads).  
 
There are several strengths and limitations of our study. Strengths include the unique 
expansion of clinical pharmacy services in a safety-net healthcare system, use of a matched 
control group, prospective data collection related to VTE outcomes, and the use of a verified 
tool to evaluate medication adherence in the intervention group.  An additional strength 
evident in the study due to clinical pharmacist involvement includes detailed medication 
profile reviews which encompass formal drug-drug interaction screening, side effect 
evaluation, and renal dose adjustments. Pharmacists also spend a significant portion of each 
clinic appointment counseling and educating patients on medication use, disease state, 
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lifestyle modifications, and smoking cessation if applicable. Limitations include slow patient 
recruitment at the start of the study, limited ability to determine the true rate of adverse 
events due to variation in documentation practices, and the use of only one anticoagulant in 
the clinic. All of these may have contributed to our small sample size and the inability to 
achieve power, as highlighted above. The retrospective nature of the data collection in the 
control group has the potential to bias results due to potential lack of documentation by the 
PCP. While most of these limitations are unavoidable, clinic volumes have since increased 
and pharmacists have added apixaban to their CPA to broaden the list of anticoagulants that 
can be prescribed. The small size of the convenience sample included in our study made 
statistical analysis demonstrating significance difficult which could have resulted in a type II 
error. Also, while we attempted to control for confounders by matching patients to 
historical controls, using a propensity score may allow for a more rigorous comparison in a 
future study utilizing a larger sample size. However, our results should be seen as 
hypothesis-generating, warranting further studies with larger patient populations or across 
multiple sites. 
 
Financial Justification of Services 
Outpatient treatment of VTE using rivaroxaban can result in significant cost savings. In a 
previously published evaluation of low-risk VTE outpatient treatment costs for 97 patients 
within the same study institution, the median cost for the first six months of care for 
patients treated with enoxaparin and warfarin was $9,016 [interquartile range (IQR) = 
$3,535 to $10,622] versus $5,932 (IQR = $4,745 to $8,594) with rivaroxaban (n=45). This six-
month median difference per patient of $3,084 approximates $515 of cost savings per 
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month of VTE treatment using rivaroxaban instead of enoxaparin and warfarin.21 We 
hypothesize that the cost savings associated with outpatient treatment of VTE using 
rivaroxaban, as compared to warfarin, is due to the decreased need for laboratory 
monitoring and subsequent provider visits.  
 
During the first 10 months of pharmacist-management in clinic, 27 unique outpatients were 
treated though not all were included in the data analysis due to not being six months from 
diagnosis. Amongst these patients, there were 182 treatment months which yields an 
estimated $93,730 of cost savings for VTE treatment using rivaroxaban instead of 
enoxaparin and warfarin (based on the cost savings described above).21 It is important to 
note that this cost savings originates from the ED physician’s decision to treat the patient 
with a low-risk VTE as an outpatient. With this decision, cost savings allowed for resources 
to be allocated toward the expansion of clinical pharmacy services, into the clot clinic. 
Additional savings could be realized when comparing the salaries and benefits required for 
clinical pharmacist hours versus primary care provider hours spent in clinic. As the time 
spent per patient visit was not documented in either group, and due to the retrospective 
nature of this study, this was not included in the estimate above.  
 
Conclusions: 
The pharmacist-managed VTE clinic using non-warfarin oral anticoagulants is a unique 
expansion of pharmacy services not yet described in the literature. Pharmacists are now 
independently managing all clot clinic patient care activities under a CPA, and have 
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expanded responsibilities to include apixaban. Pharmacists contribute distinct insight to clot 
clinic patient care by performing detailed reviews of medication lists, screening for drug 
interactions, counseling on adherence and disease state education, and ensuring 
sustainable access to their medication for the complete duration of therapy. Future 
directions include evaluating outcomes with a larger sample size, matching patients to 
controls using a propensity score, and conducting a survey to assess patient and provider 
satisfaction with the pharmacist-managed clot clinic. This study supports the expansion of 
pharmacy services in the clot clinic to promote safety, efficacy, and cost savings.   
 
Tables: 
Table 1. Patient Information Collected and Documented During Clinic Visits 
 
 Name 
 Age 
 Gender 
 Serum creatinine/creatinine clearance 
 Diagnosis (deep vein thrombosis/pulmonary embolism) and date of diagnosis 
 Provoked or unprovoked VTE 
 Previous doppler date and findings 
 D-dimer trends 
 Pertinent past medical history 
 Family or personal history of clots 
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 Smoking status 
 Patient’s primary care provider 
 Current symptoms: pain, shortness of breath, chest pain, coughing, weight changes, bleeding 
symptoms 
 Leg exam: level of swelling, calf measurements, ulceration presence, pigmentation changes 
 Medication information: concomitant anticoagulants, rivaroxaban start date, last rivaroxaban 
fill date, frequency in which patient takes rivaroxaban, current dosing, missed doses, pharmacy 
used, insurance coverage, assessment of medication adherence 
 Duration of rivaroxaban therapy 
 
Table 2. Demographic Information 
 
Demographic Information 
(N=34) 
Pharmacist-
managed Care 
Group (n=17) 
Primary Care Provider 
Group (n=17) 
P Value 
Age (years), mean (SD) 50 (12) 54(12) 0.333 
Male, n (%) 6 (35%) 6 (35%) 1.000 
Weight (kg), median (IQR) 104 (90-121) 83 (68-112) 0.098 
CrCl (mL/min), median (IQR) a 120 (120-120) 83 (68-112) 0.014 
CrCl (mL/min), median (IQR) b 81 (73-99) 69 (65-90) 0.215 
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Smoker, n (%) 5 (29%) 2 (12%) 0.215 
DVT occurrence, n (%) 14 (82%) 15 (88%) 0.398 
PE occurrence, n (%) 4 (24%) 5 (29%) 1.000 
Both DVT and PE occurrence, n 
(%) 
1 (6%) 3 (18%) 0.601 
 
 
Table 3. Secondary Outcomes Results 
 
Secondary Endpoints 
(N=34) 
Pharmacist  Care 
(n=17) 
Primary Care 
Provider Group 
 (n=17) 
P-Value 
Number of hospitalizations, n 
 
VTE-related, n 
5  
 
1  
3  
 
1 
0.688 
 
1.000 
Thromboembolic event, n (%) 1 (6%) 1 (6%) 1.000 
Fatality due to 
thromboembolism or 
bleeding, n (%) 
0 (0%) 0 (0%) 1.000 
Major bleeding, n (%) 0 (0%) 0 (0%) 1.000 
Adverse events, n (%)  7 (41%) 4 (24%) 0.465 
a Calculated using actual body weight per prescribing information recommendations 
b Calculated using ideal body weight per Cockcroft-Gault creatinine clearance equation 
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Formal medication adherence 
evaluation performed, n (%) 
8 (47%)  0 (0%) 0.003 
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